Editorial:Role of protein-protein interactions in metabolism: Genetics, structure, function by Pandey, Amit V. et al.
                                                              
University of Dundee
Editorial
Pandey, Amit V.; Henderson, Colin J; Ishii, Yuji; Kranendonk, Michel; Backes, Wayne L.;
Zanger, Ulrich M.
Published in:
Frontiers in Pharmacology
DOI:
10.3389/fphar.2017.00881
Publication date:
2017
Document Version
Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Pandey, A. V., Henderson, C. J., Ishii, Y., Kranendonk, M., Backes, W. L., & Zanger, U. M. (2017). Editorial:
Role of protein-protein interactions in metabolism: Genetics, structure, function. Frontiers in Pharmacology, 8, 1-
3. [881]. DOI: 10.3389/fphar.2017.00881
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 04. Jan. 2018
EDITORIAL
published: 27 November 2017
doi: 10.3389/fphar.2017.00881
Frontiers in Pharmacology | www.frontiersin.org 1 November 2017 | Volume 8 | Article 881
Edited and reviewed by:
Marcelo Rizzatti Luizon,
Universidade Federal de Minas Gerais,
Brazil
*Correspondence:
Amit V. Pandey
amit@pandeylab.org
Specialty section:
This article was submitted to
Pharmacogenetics and
Pharmacogenomics,
a section of the journal
Frontiers in Pharmacology
Received: 06 November 2017
Accepted: 14 November 2017
Published: 27 November 2017
Citation:
Pandey AV, Henderson CJ, Ishii Y,
Kranendonk M, Backes WL and
Zanger UM (2017) Editorial: Role of
Protein-Protein Interactions in
Metabolism: Genetics, Structure,
Function. Front. Pharmacol. 8:881.
doi: 10.3389/fphar.2017.00881
Editorial: Role of Protein-Protein
Interactions in Metabolism: Genetics,
Structure, Function
Amit V. Pandey 1, 2*, Colin J. Henderson 3, Yuji Ishii 4, Michel Kranendonk 5,
Wayne L. Backes 6 and Ulrich M. Zanger 7, 8
1 Pediatric Endocrinology, Diabetology and Metabolism, University Children’s Hospital Bern, Bern, Switzerland, 2Department
of Biomedical Research, University of Bern, Bern, Switzerland, 3Division of Cancer Research, Jacqui Wood Cancer Centre,
School of Medicine, University of Dundee, Dundee, United Kingdom, 4 Laboratory of Molecular Life Sciences, Graduate
School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan, 5Center for Toxicogenomics and Human Health
(ToxOmics), Genetics, Oncology and Human Toxicology, Universidade Nova de Lisboa, Lisbon, Portugal, 6Department of
Pharmacology and Experimental Therapeutics, Louisiana State University Health Sciences Center New Orleans, New
Orleans, LA, United States, 7Department of Molecular and Cell Biology, Dr. Margarete Fischer-Bosch-Institute of Clinical
Pharmacology, Stuttgart, Germany, 8 Eberhard Karls University of Tübingen, Tübingen, Germany
Keywords: cytochrome P450, POR, UGT, PXR, drug metabolism
Editorial on the Research Topic
Role of Protein-Protein Interactions in Metabolism: Genetics, Structure, Function
This editorial describes the articles published under our research topic “Role of protein-protein
interactions in metabolism: Genetics, structure, function.” Our aim was to bring together
researchers working on drug, steroid, and xenobiotic metabolism with interest in protein-protein
interaction for presenting their latest findings and share their opinions on recent advances in the
field. Recent advances in genetics (Meyer, 2004) and structural biology have greatly enhanced
our understanding of molecular details of diversity and differences behind control of metabolic
processes. The topic attracted a wide range of manuscripts using genetics, proteomics, biochemical,
and structural biological approaches in study of protein-protein interactions.
In six original articles, four reviews, and one mini-review, leading experts in the field described
different approaches and use of advanced technologies in the study of protein-protein interactions
related to metabolic processes.
In a review of human UDP-glucuronosyltransfares (UGTs) Fujiwara et al. discussed the current
understanding of the structure and function of UGTs in relation to protein-protein interactions and
oligomerization and summarized their own as well as other related studies on interactions of UGTs
with other proteins (Fujiwara et al., 2010). Nakamura et al. described the modification of UGT2B3
by creation of an N-glycosylation site to alter its sensitivity toward CYP3A1. It has been known
for some time that CYP3A4 can change the activities of UGTs in isoform specific manner (Ishii
et al., 2014). Rouleau et al. used a proteomics approach to study the protein-protein interactions
of human UGT1As with other proteins including UGTs, transporters, and dehydrogenases. Role
of UGTs in gene regulation as well as metabolic regulation by interactions with other proteins has
become an emerging area of interest (Audet-Delage et al., 2017).
Pavek provided a review of pregnane X receptor (PXR) interactions with other nuclear receptors
and its role in gene regulation (Rulcova et al., 2010). Ryu et al. have reviewed the interactions of
cytochrome P450 proteins (Omura, 2010; Zanger and Schwab, 2013) with themembrane associated
progesterone receptors (MAPR). Many MAPRs share similarities to cytochrome b5 and therefore
are evolutionary adapted for interactions with cytochrome P450s (Xie et al., 2011).
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Udhane et al. explored the role of genetic variations in
human NADPH cytochrome P450 oxidoreductase (POR) found
in apparently normal human population, in the metabolism
of drugs and steroid hormones. Human POR (Pandey and
Flück, 2013) is a diflavin reductase containing both the flavin
mononucleotide (FMN) and flavin adenine dinucleotide (FAD)
co-factors in separate domains that are linked by a hinge segment
and interacts with cytochrome P450 proteins (Zanger and
Schwab, 2013) and other redox partners (Pandey and Flück, 2013;
Riddick et al., 2013). Using CYP19A1 (aromatase) (Pandey et al.,
2007) for steroid metabolism and CYP3A4 for drug metabolism
(Flück et al., 2010), Udhane et al. found variable effects of POR
genetic variants in the FMNbinding and hinge regions of POR on
the activities of CYP11A1 and CYP3A4. Režen et al. studied the
polymorphisms ofCYP51A1 (Lewinska et al., 2013) for impact on
interactions with POR. Using computational models Režen et al.
predicted that CYP51A1 variants R277L and D152G have lower
binding affinity for POR.
A thorough review of the biophysical techniques used in
study of Cytochrome P450 proteins as well their interactions
with other proteins involved in xenobiotic metabolism was
provided by Lampe. By examining the X-ray crystal structures
of P450 enzymes, Reed and Backes were able to identify
potential contact points for the formation of P450-P450
complexes when interacting in membranes. This information
allows for the predictions of how P450 system proteins
are organized in the endoplasmic reticulum as well as the
functional consequences of these interactions (Davydov et al.,
2013).
Campelo et al. performed a study on the salt-induced changes
of the dynamics properties of human POR (also described as
CPR, CYPOR) by changing specific amino acids of the hinge
segment which were postulated to play a critical role in electron
transfer to its redox partners. Striking changes in the salt-profile
of cytochrome c reduction by POR were observed with several of
mutations created by Campelo et al. These results demonstrated
that both electrostatics and flexibility of the hinge segment
in POR are critical. Knowledge on the molecular mechanism
of POR’s gated electron transfer is of importance for the
understanding the crucial role POR’s for the activity of its redox-
partners. Such knowledgemay shed light on the impact of specific
human polymorphic variants of POR (Sim et al., 2009) in specific
pathologies but may also find biotechnological applications,
such as P450 mediated metabolite production (Bernhardt and
Urlacher, 2014). Degregorio et al. applied a chimeric approach
for finding the optimal redox conditions to support cytochrome
P450s reactions. A chimeric protein consisting of the reductase
domain of bacterium Bacillus megaterium BM3 and a modified
CYP3A4 was created to achieve a P450 containing its own
reductase domain for a stable and efficient electron transfer
during catalytic reactions. By using different linkers in between
reductase and P450, Degregorio et al. could achieve 2 to 3-fold
maximum velocity and coupling efficiency compared to use of
separate P450 and redox partner proteins (Munro et al., 1996).
In conclusion, this research topic illustrated the up-to-date
status of the field by leading scientists and provided a current
state of the art on the importance of protein-protein interactions
in metabolism and their role in a range of human diseases as
well as biotechnological applications of the findings obtained
from basic studies. We hope that the information gained from
publication of this research topic will stimulate research on the
role of protein-protein interactions in metabolism and facilitate
further advances in the field.
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